Abstract
Until recently, the prognosis for advanced neuroblastoma has been poor, with a high risk of recurrence after consolidation. Recently developed therapies based on monoclonal antibodies that specifically target disialoganglioside GD2 on tumor cells are improving treatment results for high-risk neuroblastoma. This article reviews the use of anti-GD2 antibodies either as monotherapy or as part of a larger and more complex treatment approach for advanced neuroblastoma. We review how anti-GD2 antibodies can be combined with other treatments or strategies to enhance their clinical effects. Tumor resistance and other problems that decrease the efficacy of anti-GD2 antibodies are discussed. Future developments in the area of anti-GD2 immunotherapies for neuroblastoma are also addressed.
Original language | English (US) |
---|---|
Pages (from-to) | 665-673 |
Number of pages | 9 |
Journal | Drugs of the Future |
Volume | 35 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2010 |
Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)